GSK · Pharma and healthcare · one day
GSK (GSK): news on Thursday 29 October 2026
News from the 24 hours to Thursday morning, 29 October 2026.
Tone of the day
−6.3strongly negative
−6.3
Relevant headlines77
Stories7
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage centred on third-quarter results, which beat estimates and kept 2026 guidance, with specialty medicines driving growth. Shares nonetheless fell sharply on weaker vaccine sales, pipeline doubts and restructuring costs, and the stock weighed on the FTSE 100.
What drove it
- Q3 results
- vaccine sales miss
- share price fall
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Fri 23 Oct | +7.2 | 18 |
| Sat 24 Oct | +8.0 | 15 |
| Sun 25 Oct | +2.0 | 6 |
| Mon 26 Oct | +5.7 | 5 |
| Tue 27 Oct | +9.3 | 29 |
| Wed 28 Oct | +7.0 | 23 |
| Thu 29 Oct | −6.3 | 77 |
7 stories · 77 headlines · strongest first
Pharma and healthcare on 29 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| GSK reports third-quarter results, keeps 2026 outlook; shares fall on vaccines −3.069 headlines today · 77 in all, since 24 October · Previews look ahead to GSK's third-quarter results and analyst expectations. | ||
| −10.0 | Shares fell on weaker sales and rising costs. | |
| −10.0 | Shares fell on vaccines and restructuring charges. | |
| −10.0 | Shares fell sharply as vaccine sales worried investors. | |
| −9.2 | Shares slumped as vaccine sales declined. | |
| −9.2 | Vaccine sales missed forecasts on weaker adult demand. | |
| −9.2 | Vaccine and HIV stumbles erased prior share gains. | |
| −9.2 | Shares fell after vaccine disappointment. | |
| −9.2 | Shares hit by disappointing vaccine sales. | |
| −9.2 | Shares dropped sharply on vaccine weakness and pipeline concerns. | |
| −8.3 | Shares slumped on falling vaccine sales. | |
| −8.3 | Shares slipped on weaker vaccine sales. | |
| +8.3 | Company's own upbeat description of quarter. | |
| −8.3 | Pipeline doubts and vaccine weakness outweigh sales beat. | |
| −8.3 | Lower vaccine revenue weighed on GSK's share price. | |
| −8.3 | Among biggest index fallers after results. | |
| −8.3 | Shares sank as vaccine sales declined. | |
| −8.3 | Shares dropped despite revenue growth. | |
| −8.3 | Explains intraday share slide. | |
| −7.5 | Fell despite beating forecasts; cautious profit outlook. | |
| −7.5 | Falling vaccine sales dulled results. | |
| −7.5 | Profit fell during cost-cutting restructuring. | |
| −7.5 | Key products disappointed despite trial plans. | |
| −7.5 | Share losses weighed on the index after results. | |
| −7.5 | Vaccine concerns hurt the shares. | |
| −6.7 | Beat failed to satisfy, shares down. | |
| −6.7 | Named among biggest FTSE fallers on results day. | |
| −6.7 | Its losses held the index back. | |
| −6.7 | Beat failed to satisfy, shares down. | |
| +6.7 | Bullish investor view after strong quarter. | |
| −6.7 | Its decline dragged the London index. | |
| −6.7 | Profit fell amid cost-cutting. | |
| +6.7 | Presentation highlights specialty growth and faster pipeline. | |
| −5.8 | Named as disappointing in morning market report. | |
| −5.8 | Analysis flags upcoming HIV challenges despite conference enthusiasm.} | |
| −5.8 | Vaccine weakness overshadowed better-than-expected earnings. | |
| −5.8 | Results weighed on London stocks. | |
| +5.8 | Beat estimates on new medicines, outlook retained. | |
| −5.8 | Large restructuring costs dented quarterly earnings. | |
| −5.8 | Vaccine weakness spoiled an otherwise better result. | |
| +5.0 | Specialty growth, cash generation and unchanged guidance viewed positively. | |
| +5.0 | Specialty medicines drove growth and beat forecasts. | |
| −5.0 | Beat on earnings but shares fell on soft vaccines. | |
| −5.0 | Beat overshadowed by soft sales and patent issues. | |
| +5.0 | Earnings and revenue beat forecasts. | |
| −5.0 | Beat, but key vaccines Shingrix and Arexvy underperformed. | |
| −5.0 | Results weighed on the market in the morning. | |
| +5.0 | Earnings per share ahead of forecast with outlook given. | |
| +5.0 | Earnings and revenue ahead of analysts' expectations. | |
| +4.2 | Guidance maintained and specialty sales lifted revenue. | |
| −3.3 | Market update covering its results among others. | |
| −3.3 | Market commentary featuring its results. | |
| −3.3 | Lower operating profit offsets cancer approvals. | |
| +3.3 | Analyst sees share price fall as buying opportunity despite vaccine shortfall. | |
| −3.3 | Beat estimates but premarket share decline. | |
| +1.7 | Solid quarter with major transformation underway. | |
| +1.7 | Specialty double-digit growth balanced by weaker vaccines despite beat. | |
| +0.8 | Guidance held but cost and pricing pressures noted. | |
| +0.8 | Core earnings slightly lower, sales up, outlook unchanged. | |
| +0.8 | Sales growth from specialty offset by China vaccine destocking. | |
| 0.0 | Recap of management comments on call. | |
| 0.0 | Call transcript, factual. | |
| 0.0 | Earnings call item, factual. | |
| 0.0 | Transcript of quarterly call, factual. | |
| 0.0 | Results presentation, factual. | |
| 0.0 | Earnings summary, factual. | |
| 0.0 | Official results filing summary. | |
| 0.0 | Call transcript, factual. | |
| 0.0 | Plain report of quarterly revenue. | |
| 0.0 | Brief factual earnings summary. | |
| Brokers rate GSK +0.83 headlines today · 10 in all, since 22 October · JP Morgan has a Sell rating, while Bernstein stays at Buy and RBC at Neutral. | ||
| −8.3 | Bank analyst has negative rating. | |
| +5.0 | Broker maintains positive rating. | |
| 0.0 | Broker keeps middle-of-the-road rating. | |
| GSK forecasts almost twice as many cancer drugs in trials in 2027 +8.21 headline today · 8 in all, since 28 October · WSJ and others report GSK expects its clinical cancer pipeline to nearly double next year after dealmaking. | ||
| +7.5 | Plans to greatly expand late-stage cancer pipeline. | |
| Hibsago prepares for US hepatitis B launch after GSK approvals +5.01 headline today · Fierce Pharma reports GSK is preparing a concentrated US launch of Hibsago for hepatitis B. | ||
| +5.0 | Approvals lead to planned US hepatitis B launch. | |
| GSK expects limited impact on UK jobs from restructuring −4.21 headline today · GSK said its restructuring will have some limited effect on UK roles. | ||
| −4.2 | Restructuring will affect some UK jobs. | |
| GSK commits to transparency in reporting +3.31 headline today · A piece reports GSK's pledge on transparency in its disclosures. | ||
| +3.3 | Commitment to greater transparency. | |
| GSK declares quarterly dividend of 17p per share +1.71 headline today · GSK announced a dividend of 17p per share, or $0.4524 per ADS. | ||
| +1.7 | Routine dividend declaration. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.